REGENERON PHARMACEUTICALS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $987.91 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-03
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $987.91M, a 15.11% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $978.72M, a 13.47% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $957.37M, a 11.65% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $924.13M, a 10.78% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $3.72B, a 11.38% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $3.34B, a 24.13% increase from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $2.69B, a 53.62% increase from fiscal 2014.
- REGENERON PHARMACEUTICALS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $1.75B, a 22.79% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $987.91M 10-Q · filed 2018-05-03 | $1.97B derived: sum of 2 quarters · filed 2018-05-03 | $2.92B derived: sum of 3 quarters · filed 2018-05-03 | $3.85B derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | $978.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $1.94B derived: sum of 2 quarters · filed 2018-02-08 | $2.86B derived: sum of 3 quarters · filed 2018-02-08 | $3.72B 10-K · filed 2018-02-08 |
| 2017-09-30 | $957.37M 10-Q · filed 2017-11-08 | $1.88B derived: sum of 2 quarters · filed 2017-11-08 | $2.74B 10-Q · filed 2017-11-08 | $3.60B derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-06-30 | $924.13M 10-Q · filed 2017-08-03 | $1.78B 10-Q · filed 2017-08-03 | $2.64B derived: sum of 3 quarters · filed 2018-05-03 | $3.50B derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-03-31 | $858.25M 10-Q · filed 2018-05-03 | $1.72B derived: sum of 2 quarters · filed 2018-05-03 | $2.58B derived: sum of 3 quarters · filed 2018-05-03 | $3.41B derived: sum of 4 quarters · filed 2018-05-03 |
| 2016-12-31 | $862.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $1.72B derived: sum of 2 quarters · filed 2018-02-08 | $2.55B derived: sum of 3 quarters · filed 2018-02-08 | $3.34B 10-K · filed 2018-02-08 |
| 2016-09-30 | $857.47M 10-Q · filed 2017-11-08 | $1.69B derived: sum of 2 quarters · filed 2017-11-08 | $2.48B 10-Q · filed 2017-11-08 | $3.23B derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-06-30 | $834.22M 10-Q · filed 2017-08-03 | $1.62B 10-Q · filed 2017-08-03 | $2.37B derived: sum of 3 quarters · filed 2018-02-08 | $3.11B derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-03-31 | $784.18M 10-Q · filed 2017-05-04 | $1.53B derived: sum of 2 quarters · filed 2018-02-08 | $2.27B derived: sum of 3 quarters · filed 2018-02-08 | $2.93B derived: sum of 4 quarters · filed 2018-02-08 |
| 2015-12-31 | $749.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $1.49B derived: sum of 2 quarters · filed 2018-02-08 | $2.14B derived: sum of 3 quarters · filed 2018-02-08 | $2.69B 10-K · filed 2018-02-08 |
| 2015-09-30 | $737.56M 10-Q · filed 2016-11-04 | $1.40B derived: sum of 2 quarters · filed 2016-11-04 | $1.94B 10-Q · filed 2016-11-04 | $2.46B derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-06-30 | $657.82M 10-Q · filed 2016-08-04 | $1.20B 10-Q · filed 2016-08-04 | $1.72B derived: sum of 3 quarters · filed 2017-02-09 | $2.17B derived: sum of 4 quarters · filed 2017-02-09 |
| 2015-03-31 | $544.57M 10-Q · filed 2016-05-05 | $1.07B derived: sum of 2 quarters · filed 2017-02-09 | $1.51B derived: sum of 3 quarters · filed 2017-02-09 | $1.93B derived: sum of 4 quarters · filed 2017-02-09 |
| 2014-12-31 | $521.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $970.36M derived: sum of 2 quarters · filed 2017-02-09 | $1.39B derived: sum of 3 quarters · filed 2017-02-09 | $1.75B 10-K · filed 2017-02-09 |
| 2014-09-30 | $448.84M 10-Q · filed 2015-11-04 | $866.87M derived: sum of 2 quarters · filed 2015-11-04 | $1.23B 10-Q · filed 2015-11-04 | $1.64B derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $418.02M 10-Q · filed 2015-08-04 | $780.40M 10-Q · filed 2015-08-04 | $1.19B derived: sum of 3 quarters · filed 2016-02-11 | $1.55B derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $362.38M 10-Q · filed 2015-05-07 | $768.47M derived: sum of 2 quarters · filed 2016-02-11 | $1.14B derived: sum of 3 quarters · filed 2016-02-11 | $1.47B derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $406.09M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $773.21M derived: sum of 2 quarters · filed 2016-02-11 | $1.11B derived: sum of 3 quarters · filed 2016-02-11 | $1.43B 10-K · filed 2016-02-11 |
| 2013-09-30 | $367.12M 10-Q · filed 2014-11-04 | $701.01M derived: sum of 2 quarters · filed 2014-11-04 | $1.02B 10-Q · filed 2014-11-04 | $1.30B derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-06-30 | $333.89M 10-Q · filed 2014-08-05 | $652.63M 10-Q · filed 2014-08-05 | $934.10M derived: sum of 3 quarters · filed 2015-02-12 | $1.18B derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-03-31 | $318.74M 10-Q · filed 2014-05-08 | $600.21M derived: sum of 2 quarters · filed 2015-02-12 | $849.38M derived: sum of 3 quarters · filed 2015-02-12 | $1.05B derived: sum of 4 quarters · filed 2015-02-12 |
| 2012-12-31 | $281.47M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $530.64M derived: sum of 2 quarters · filed 2015-02-12 | $730.16M derived: sum of 3 quarters · filed 2015-02-12 | $858.09M 10-K · filed 2015-02-12 |
| 2012-09-30 | $249.17M 10-Q · filed 2013-11-05 | $448.69M derived: sum of 2 quarters · filed 2013-11-05 | $576.62M 10-Q · filed 2013-11-05 | $606.37M derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-06-30 | $199.52M 10-Q · filed 2013-08-06 | $327.45M 10-Q · filed 2013-08-06 | $357.20M derived: sum of 3 quarters · filed 2014-02-13 | $362.67M derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-03-31 | $127.93M 10-Q · filed 2013-05-03 | $157.68M derived: sum of 2 quarters · filed 2014-02-13 | $163.15M derived: sum of 3 quarters · filed 2014-02-13 | $168.19M derived: sum of 4 quarters · filed 2014-02-13 |
| 2011-12-31 | $29.75M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $35.22M derived: sum of 2 quarters · filed 2014-02-13 | $40.26M derived: sum of 3 quarters · filed 2014-02-13 | $44.69M 10-K · filed 2014-02-13 |
| 2011-09-30 | $5.47M 10-Q · filed 2012-10-24 | $10.51M derived: sum of 2 quarters · filed 2012-10-24 | $14.93M 10-Q · filed 2012-10-24 | $20.20M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $5.04M 10-Q · filed 2012-07-25 | $9.47M 10-Q · filed 2012-07-25 | $14.73M derived: sum of 3 quarters · filed 2013-02-15 | $19.67M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $4.43M 10-Q · filed 2012-04-26 | $9.70M derived: sum of 2 quarters · filed 2013-02-15 | $14.63M derived: sum of 3 quarters · filed 2013-02-15 | $19.83M derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $10.21M derived: sum of 2 quarters · filed 2013-02-15 | $15.40M derived: sum of 3 quarters · filed 2013-02-15 | $25.25M 10-K · filed 2013-02-15 |
| 2010-09-30 | $4.94M 10-Q · filed 2011-10-27 | $10.13M derived: sum of 2 quarters · filed 2011-10-27 | $19.98M 10-Q · filed 2011-10-27 | $24.98M derived: sum of 4 quarters · filed 2012-02-21 |
| 2010-06-30 | $5.20M 10-Q · filed 2011-07-28 | $15.05M 10-Q · filed 2011-07-28 | $20.05M derived: sum of 3 quarters · filed 2012-02-21 | $25.02M derived: sum of 4 quarters · filed 2012-02-21 |
| 2010-03-31 | $9.85M 10-Q · filed 2011-05-03 | $14.85M derived: sum of 2 quarters · filed 2012-02-21 | $19.82M derived: sum of 3 quarters · filed 2012-02-21 | $24.32M derived: sum of 4 quarters · filed 2012-02-21 |
| 2009-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $9.97M derived: sum of 2 quarters · filed 2012-02-21 | $14.47M derived: sum of 3 quarters · filed 2012-02-21 | $18.36M 10-K · filed 2012-02-21 |
| 2009-09-30 | $4.97M 10-Q · filed 2010-10-28 | $9.47M derived: sum of 2 quarters · filed 2010-10-28 | $13.36M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $4.50M 10-Q · filed 2010-07-28 | $8.39M 10-Q · filed 2010-07-28 | ||
| 2008-12-31 | $6.25M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |